Page Title
Drug Development Pipeline
Lenabasum (JBT-101)
Status
DiscontinuedTherapeutic Approach
Anti-Inflammatory
Lenabasum (JBT-101) is an oral drug that is aimed at promoting the resolution of inflammation. It is thought to increase production of anti-inflammatory molecules while reducing production of molecules that increase inflammation. Reduction of inflammation helps prevent permanent tissue damage in the lungs.
Status
A phase 2 trial of lenabasum did not meet its primary endpoint of decreasing pulmonary exacerbations in people with cystic fibrosis. There is no active development in CF at this time.
Sponsor
This program was sponsored by Corbus and partially funded by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More